95% accuracy, 92.5% sensitivity and 99% specificity in pre-clinical studies with unstained inner cervical smear samples.

95% accuracy, 92.5% sensitivity and 99% specificity in pre-clinical studies with unstained inner cervical smear samples.

95% accuracy, 92.5% sensitivity and 99% specificity in pre-clinical studies with unstained inner cervical smear samples.

Tumour Trace

Tumour Trace technology delivers results within minutes, at less cost and accuracy close to the gold standard.

Method

Our patented Opto-Magnetic Imaging Spectroscopy (OMIS) brings together optical reflectance microscopy and Brewster angle microscopy into a method that is able to differentiate between normal and cancerous samples.

Read more>>

Validation

The method does not rely on specific cancer biomarkers and is therefore theoretically able to detect any cancer. We have validated the method with cervical, bowel and prostate cancers using epithelial tissues, biopsies and blood plasma.

Read more>>

Impact

Tumour Trace’s method has the potential to revolutionise early cancer detection. With accuracy close to the gold standard and at a price orders of magnitude less than current techniques, Tumour Trace is working to make cancer screening available to everyone, everywhere.